Bladder cancer poses a significant global health challenge, with a complex pathogenesis that includes a subpopulation of cancer stem cells (CSCs) contributing to therapy resistance and tumor recurrence.
Identifying and understanding the role of CSC markers are crucial for developing targeted therapies and improving prognosis.
